echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The breakthrough of pediatric medicine market requires the concerted efforts of all sectors of society

    The breakthrough of pediatric medicine market requires the concerted efforts of all sectors of society

    • Last Update: 2015-12-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: economic reference report 2015-12-18 With regard to the children's drug market, good news has come in succession recently Jiangsu, Guangdong and other provinces have raised the price of children's drugs into the market The State Food and drug administration has also listed the priority policies for the approval of children's drug use in its announcement Before that, the state health and Family Planning Commission has also established a special committee for children's drug use to promote the inclusion of children's drug use in the medical insurance catalog In addition, the second child policy has contributed to the market The field is about to break out But on the other hand, 16.02 + 0.020.13% of Chinese medicine, on the one hand, because of the particularity and huge investment of pediatric medicine market, many enterprises are also deterred Industry personages suggest that the ice breaking of pediatric medicine market, in addition to some industry leaders, needs the joint promotion of all sectors of society Children's medicine market in China is relatively special, and Chinese children are facing a serious crisis The data shows that children's drugs in China are faced with the problems of difficult clinical research, few varieties of drugs and lack of proprietary dosage forms More than 90% of drugs do not have children's dosage forms There are about 6000 pharmaceutical enterprises in China, but there are only about 10 professional children pharmaceutical enterprises In China, 180000 drug registration numbers have been approved, but only more than 3000 registration numbers for children's special drugs, accounting for only 1.7% Due to the lack of special drugs, children take adult drugs directly, and overdose or lack of drugs will bury health risks For a long time, the market of Pediatrics in China is in a relatively blank period China's population under 12 years old has exceeded 200 million, and the market demand is huge, which contains more development opportunities and innovation space, but on the other hand, there are only a few enterprises that really devote themselves to the pediatric medicine industry, and this market seems to be a hot potato Although the market of children's medicine in China has a bright future, compared with adult medicine, there are too many challenges in research and development, production and commercialization of children's medicine According to the insiders, children's drug dosage is small, seasonal and difficult in clinical trials, which makes the overall profit of children's drug use low The prescription and technology of children's drug use are relatively complex, and the requirements for taste, safety, raw and auxiliary materials selectivity and quality control are very high Due to the narrow age, it is necessary to develop a variety of dosage forms, specifications or packaging High difficulty, low profit and high risk Countless medicines are waiting for them In recent years, the development of the market requires the joint efforts of all parties in the society Relevant domestic medical institutions, associations and government departments have frequently called for "tailor-made children's drugs" in various conferences, but few enterprises have really responded to the call and carried out strategic transformation or product layout adjustment Throughout the country, the drug companies that implement the concept of "customized children's drugs" are basically the well-known enterprises of pediatric medicine, such as dyne pharmaceutical For the future development of children's pharmaceutical industry, Yang Jie, general manager of dyne pharmaceutical industry, put forward the eight word strategic proposal of "top-level design, collaborative cooperation", and pointed out that in the future, China should combine production, learning and research closely to build research and development institutions and technical platforms for children's specific drugs; At the same time, enterprises and hospitals should continue to strengthen cooperation and apply for registration of "drug approval" for hospital internal preparations with long-term clinical application experience and safety and effectiveness; In addition, major pharmaceutical enterprises should also work together Through the platform of "children's medicine professional committee of China Pharmaceutical Enterprise Management Association", we can exchange and cooperate, make joint efforts, and jointly promote the healthy development of China's children's pharmaceutical industry It is the adherence to the cause of Pediatrics and the continuous practice of the enterprise mission of "making millions of Chinese children healthy and strong" From a small state-owned pharmaceutical factory on the verge of bankruptcy in 1994, dyne pharmaceutical has grown into a leading professional brand enterprise of children's medicine in the industry The products of dyne pharmaceutical include the well-known icoxin vitamin AD drops, gedixin compound calcium carbonate effervescent granules, iganxin Glycyrrhiza zinc granules and so on In recent years, dyne pharmaceutical industry has begun to make efforts in the field of children's products and children's food, and has successively launched children's antipyretic stickers and other children's health-related products The process of drug design, development, test and approval is very strict, especially for children's special drugs Therefore, it seems that the dyne pharmaceutical industry, which is standing at the tuyere, is not easy to fly Under the leadership of general manager Yang Jie, dyne pharmaceutical attaches great importance to scientific and technological innovation and R & D, and actively carries out the research work of customized children's drugs Since 2007, dyne pharmaceutical has approved more than 60 children's drugs, involving the research of children's common diseases, frequently occurring diseases and some rare disease treatment drugs, all of which are special specifications and dosage forms for children.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.